> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-66/
- Published: 2022-03-13T12:00:00.000Z
- Updated: 2026-09-14T17:36:18.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138635

**Ipsen** has completed an acquisition of a portfolio of five international consumer healthcare products from **Sanofi**: Prontalgine, an analgesic for treating moderate to severe pain; Buscopan, an antispasmodic, Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, expectorants for cough and flu.

**Horizon Pharma** has agreed to acquire **River Vision Development Corp.** and its development-stage medicine teprotumumab (RV001), a fully human monoclonal antibody (mAb) currently in development for thyroid eye disease, a rare, autoimmune inflammatory disorder. Under the terms of the agreement, Horizon Pharma will acquire all outstanding equity of River Vision for an upfront cash payment of $145 million, plus potential future milestone and earn-out payments.

Bruker says it has acquired Luxendo, a privately held spin-off of the **European Molecular Biology Laboratory** that develops and manufactures proprietary light-sheet fluorescence microscopy instruments. Luxendo’s proprietary single-plane illumination microscopy technique reportedly reduces sampling times over conventional laser scanning confocal microscopes, while reducing phototoxicity and damaging side effects on living specimens.